Skip to main content
Erschienen in:

01.01.2007 | Leitthema

Prädiktive Biomarker

Die Schlüsselrolle der Molekularpathologie

verfasst von: Prof. Dr. M. Dietel

Erschienen in: Die Onkologie | Ausgabe 1/2007

Einloggen, um Zugang zu erhalten

Zusammenfassung

Die Forderung von Klinikern und Patienten nach exakter Prädiktion des biologischen Verhaltens von Malignomen stellt die größte aktuelle Herausforderung für die diagnostische Molekularpathologie dar. Die Möglichkeit, mittels gewebebasierter High-Throughput-Techniken die Prognose, die Metastasierungswahrscheinlichkeit und das Ansprechen auf antiproliferative Medikamente für den einzelnen Patienten mit hoher Präzision prädiktiv zu bestimmen, wird die onkologische Therapie zukünftig verändern und die individualisierte Behandlung der Patienten Realität werden lassen. Dies würde eine wirksamere Therapie mit weniger Nebenwirkungen ermöglichen. Auf dem Boden der Erkenntnis, dass die Effektivität neuer Substanzen nur unter Zuhilfenahme von humanem Tumormaterial zuverlässig bestimmt werden kann, werden die Pathologie und deren Gewebebanken eine Schlüsselrolle auch in der pharmazeutischen Entwicklung neuer Antikrebsmittel spielen.
Literatur
1.
Zurück zum Zitat Abdul-Ghani R, Serra V, Gyorffy B et al. (2006) The PI3 K inhibitor LY294002 blocks drug export from resistant colon carcinoma cells overexpressing MRP1. Oncogene 25: 1743–52.CrossRefPubMed Abdul-Ghani R, Serra V, Gyorffy B et al. (2006) The PI3 K inhibitor LY294002 blocks drug export from resistant colon carcinoma cells overexpressing MRP1. Oncogene 25: 1743–52.CrossRefPubMed
2.
Zurück zum Zitat Albitar M, Potts SJ, Giles FJ et al. (2006) Proteomic-based prediction of clinical behavior in adult acute lymphoblastic leukemia. Cancer 106: 1587–1594CrossRefPubMed Albitar M, Potts SJ, Giles FJ et al. (2006) Proteomic-based prediction of clinical behavior in adult acute lymphoblastic leukemia. Cancer 106: 1587–1594CrossRefPubMed
3.
Zurück zum Zitat Alizadeh AA, Eisen MB, Davis RE et al. (2000) Distinct types of diffuse large B-cell lymphoma identified by gene expression profiling. Nature 403: 503–511CrossRefPubMed Alizadeh AA, Eisen MB, Davis RE et al. (2000) Distinct types of diffuse large B-cell lymphoma identified by gene expression profiling. Nature 403: 503–511CrossRefPubMed
4.
Zurück zum Zitat Armstrong SA, Staunton JE, Silverman LB et al. (2002) MLL translocations specify a distinct gene expression profile that distinguishes a unique leukemia. Nat Genet 30: 41–47CrossRefPubMed Armstrong SA, Staunton JE, Silverman LB et al. (2002) MLL translocations specify a distinct gene expression profile that distinguishes a unique leukemia. Nat Genet 30: 41–47CrossRefPubMed
5.
Zurück zum Zitat Bammler T, Beyer RP, Bhattacharya S et al. (2005) Standardizing global gene expression analysis between laboratories and across platforms. Nature Methods 2: 351–356CrossRefPubMed Bammler T, Beyer RP, Bhattacharya S et al. (2005) Standardizing global gene expression analysis between laboratories and across platforms. Nature Methods 2: 351–356CrossRefPubMed
6.
Zurück zum Zitat Baylin SB, Esteller M, Rountree MR et al. (2001) Aberrant patterns of DNA methylation, chromatin formation and gene expression in cancer. Hum Mol Genet 10: 687–692CrossRefPubMed Baylin SB, Esteller M, Rountree MR et al. (2001) Aberrant patterns of DNA methylation, chromatin formation and gene expression in cancer. Hum Mol Genet 10: 687–692CrossRefPubMed
7.
Zurück zum Zitat Bernard PS und Wittwer CT (2002) Real-time PCR technology for cancer diagnostics. Clinical Chemistry 48: 1178–1185PubMed Bernard PS und Wittwer CT (2002) Real-time PCR technology for cancer diagnostics. Clinical Chemistry 48: 1178–1185PubMed
8.
Zurück zum Zitat Bhattacharjee A, Richards WG, Staunton J et al. (2001) Classification of human lung carcinomas by mRNA expression profiling reveals distinct adenocarcinoma subclasses. Proc Natl Acad Sci USA 98: 13790–13795CrossRefPubMed Bhattacharjee A, Richards WG, Staunton J et al. (2001) Classification of human lung carcinomas by mRNA expression profiling reveals distinct adenocarcinoma subclasses. Proc Natl Acad Sci USA 98: 13790–13795CrossRefPubMed
9.
Zurück zum Zitat Bittner M, Meltzer P, Chen Y et al. (2000) Molecular classification of cutaneous malignant melanoma by gene expression profiling. Nature 406: 536–540CrossRef Bittner M, Meltzer P, Chen Y et al. (2000) Molecular classification of cutaneous malignant melanoma by gene expression profiling. Nature 406: 536–540CrossRef
10.
Zurück zum Zitat Brazma A, Hingamp P, Quackenbush J et al. (2001) Minimum information about a microarray experiment (MIAME): toward standards for microarray data. Nat Genet 29: 365–371CrossRefPubMed Brazma A, Hingamp P, Quackenbush J et al. (2001) Minimum information about a microarray experiment (MIAME): toward standards for microarray data. Nat Genet 29: 365–371CrossRefPubMed
12.
Zurück zum Zitat Brenton JD, Carey LA, Ahmed AA et al. (2005) Molecular classification and molecular forecasting of breast cancer: ready for clinical apllication? J Clin Oncol 23: 7350–7360 Brenton JD, Carey LA, Ahmed AA et al. (2005) Molecular classification and molecular forecasting of breast cancer: ready for clinical apllication? J Clin Oncol 23: 7350–7360
13.
Zurück zum Zitat Cai Z, Chiu JF, He QY (2004). Application of proteomics in the study of tumor metastasis. Genomics Proteomics Bioinformatics 3: 152–166 Cai Z, Chiu JF, He QY (2004). Application of proteomics in the study of tumor metastasis. Genomics Proteomics Bioinformatics 3: 152–166
14.
Zurück zum Zitat Celis JE, Kruhoffer M, Gromova I et al. (2000) Gene expression profiling: monitoring transcription and translation products using DNA microarrays and proteomics. FEBS Lett 480: 2–16CrossRefPubMed Celis JE, Kruhoffer M, Gromova I et al. (2000) Gene expression profiling: monitoring transcription and translation products using DNA microarrays and proteomics. FEBS Lett 480: 2–16CrossRefPubMed
15.
Zurück zum Zitat Chen J, Kähne T, Röcken C et al. (2004) Proteome analysis of gastric cancer metastasis by two-dimensional gel electrophoresis and matrix assisted laser desorption/ionization-mass spectrometry for identification of metastasis-related proteins. J Proteome Res 3: 1009–1016CrossRefPubMed Chen J, Kähne T, Röcken C et al. (2004) Proteome analysis of gastric cancer metastasis by two-dimensional gel electrophoresis and matrix assisted laser desorption/ionization-mass spectrometry for identification of metastasis-related proteins. J Proteome Res 3: 1009–1016CrossRefPubMed
16.
Zurück zum Zitat Choi YP, Kang S, Hong S et al. (2005) Proteomic analysis of progressive factors in uterine cervical cancer. Proteomics 5: 1481–1493CrossRefPubMed Choi YP, Kang S, Hong S et al. (2005) Proteomic analysis of progressive factors in uterine cervical cancer. Proteomics 5: 1481–1493CrossRefPubMed
17.
Zurück zum Zitat Cottrell SE, Distler J, Goodman NS et al. (2004) A real-time PCR assay for DNA-methylation using methylationspecific blockers. Nucleic Acids Res 32: e10CrossRefPubMed Cottrell SE, Distler J, Goodman NS et al. (2004) A real-time PCR assay for DNA-methylation using methylationspecific blockers. Nucleic Acids Res 32: e10CrossRefPubMed
18.
Zurück zum Zitat Cui JW, Li WH, Wang J et al. (2005) Proteomics-based identification of human acute leukemia antigens that induce humoral immune response. Mol Cell Proteomics 4: 1718–1724CrossRefPubMed Cui JW, Li WH, Wang J et al. (2005) Proteomics-based identification of human acute leukemia antigens that induce humoral immune response. Mol Cell Proteomics 4: 1718–1724CrossRefPubMed
19.
Zurück zum Zitat Dancey J, Sausville EA (2003) Issues and progress with protein kinase inhibitors for cancer treatment. Nat Rev Drug Discov 2: 296–313CrossRefPubMed Dancey J, Sausville EA (2003) Issues and progress with protein kinase inhibitors for cancer treatment. Nat Rev Drug Discov 2: 296–313CrossRefPubMed
20.
Zurück zum Zitat Dhanasekaran SM, Barrette TR, Ghosh D et al. (2001) Delineation of prognostic biomarkers in prostate cancer. Nature 412: 822–826CrossRefPubMed Dhanasekaran SM, Barrette TR, Ghosh D et al. (2001) Delineation of prognostic biomarkers in prostate cancer. Nature 412: 822–826CrossRefPubMed
21.
Zurück zum Zitat Diamandis EP (2006) Serum proteomic profiling by matrix-assisted laser desorption-ionization time-of-flight mass spectrometry for cancer diagnosis: next steps. Cancer Res 66: 5540–5541CrossRefPubMed Diamandis EP (2006) Serum proteomic profiling by matrix-assisted laser desorption-ionization time-of-flight mass spectrometry for cancer diagnosis: next steps. Cancer Res 66: 5540–5541CrossRefPubMed
22.
Zurück zum Zitat Dietel M, Sers C (2006) Personalized medicine and development of targeted therapies: the upcoming challenge for diagnostic molecular pathology. A review. Virch Arch 448: 744–755CrossRef Dietel M, Sers C (2006) Personalized medicine and development of targeted therapies: the upcoming challenge for diagnostic molecular pathology. A review. Virch Arch 448: 744–755CrossRef
23.
Zurück zum Zitat Ebert M, Krüger S, Fogeron ML et al. (2005) Overexpression of Cathepsin B in gastric cancer identified by proteome analysis. Proteomics 5: 1693–7104CrossRefPubMed Ebert M, Krüger S, Fogeron ML et al. (2005) Overexpression of Cathepsin B in gastric cancer identified by proteome analysis. Proteomics 5: 1693–7104CrossRefPubMed
24.
Zurück zum Zitat Ebert MP, Röcken C (2006) Molecular screening of gastric cancer by proteome analysis. Eur J Gastroenterol Hepatol 18: 847–853CrossRefPubMed Ebert MP, Röcken C (2006) Molecular screening of gastric cancer by proteome analysis. Eur J Gastroenterol Hepatol 18: 847–853CrossRefPubMed
25.
Zurück zum Zitat Eisen MB, Spellman PT, Brown PO et al. (1998) Cluster analysis and display of genome-wide expression patterns. Proc Natl Acad Sci USA 95: 14863–14868CrossRefPubMed Eisen MB, Spellman PT, Brown PO et al. (1998) Cluster analysis and display of genome-wide expression patterns. Proc Natl Acad Sci USA 95: 14863–14868CrossRefPubMed
26.
Zurück zum Zitat Eschrich S, Yang I, Bloom G et al. (2005) Molecular staging for survival prediction of colorectal cancer patients. J Clin Oncol 23: 3526–3535CrossRefPubMed Eschrich S, Yang I, Bloom G et al. (2005) Molecular staging for survival prediction of colorectal cancer patients. J Clin Oncol 23: 3526–3535CrossRefPubMed
27.
Zurück zum Zitat Fan C, Oh DS, Wessels L et al. (2006) Concordance among gene-expression–based predictors for breast cancer. N Engl J Med 355: 560–569CrossRefPubMed Fan C, Oh DS, Wessels L et al. (2006) Concordance among gene-expression–based predictors for breast cancer. N Engl J Med 355: 560–569CrossRefPubMed
28.
Zurück zum Zitat Feng YX, Bai J, Zhang CY et al. (2006) Proteomic analysis for the identification of proteins related to methotrexate resistance. Yi Chuan Xue Bao 33: 391–396PubMed Feng YX, Bai J, Zhang CY et al. (2006) Proteomic analysis for the identification of proteins related to methotrexate resistance. Yi Chuan Xue Bao 33: 391–396PubMed
29.
Zurück zum Zitat Fung ET, Yip TT, Lomas L et al. (2005) Classification of cancer types by measuring variants of host response proteins using SELDI serum assays. Int J Cancer 115: 783–789CrossRefPubMed Fung ET, Yip TT, Lomas L et al. (2005) Classification of cancer types by measuring variants of host response proteins using SELDI serum assays. Int J Cancer 115: 783–789CrossRefPubMed
30.
Zurück zum Zitat Garber K (2004) Gene expression tests foretell breast cancer’s future. Science 303: 1754–1755CrossRefPubMed Garber K (2004) Gene expression tests foretell breast cancer’s future. Science 303: 1754–1755CrossRefPubMed
31.
Zurück zum Zitat Garber ME, Troyanskaya OG, Schluens K et al. (2001) Diversity of gene expression in adenocarcinoma of the lung. Proc Natl Acad Sci USA 98: 13784–13789CrossRefPubMed Garber ME, Troyanskaya OG, Schluens K et al. (2001) Diversity of gene expression in adenocarcinoma of the lung. Proc Natl Acad Sci USA 98: 13784–13789CrossRefPubMed
32.
Zurück zum Zitat Golub TR, Slonim DK, Tamayo P et al. (1999) Molecular classification of cancer: class discovery and class prediction by gene expression monitoring. Science 286: 531–537CrossRefPubMed Golub TR, Slonim DK, Tamayo P et al. (1999) Molecular classification of cancer: class discovery and class prediction by gene expression monitoring. Science 286: 531–537CrossRefPubMed
33.
Zurück zum Zitat Gutman S, Kessler LG (2006) The US Food and Drug Administration perspective on cancer biomarker development. Nature Rev Cancer 6: 565–571CrossRef Gutman S, Kessler LG (2006) The US Food and Drug Administration perspective on cancer biomarker development. Nature Rev Cancer 6: 565–571CrossRef
34.
Zurück zum Zitat Györffy B, Serra V, Jurchott K et al. (2005) Prediction of doxorubicin sensitivity in breast tumors based on gene expression profiles of drug-resistant cell lines correlates with patient survival. Oncogene 24: 7542–7551CrossRefPubMed Györffy B, Serra V, Jurchott K et al. (2005) Prediction of doxorubicin sensitivity in breast tumors based on gene expression profiles of drug-resistant cell lines correlates with patient survival. Oncogene 24: 7542–7551CrossRefPubMed
35.
Zurück zum Zitat Györffy B, Surowiak P, Kiesslich O et al. (2006) Gene expression profiling of 30 cancer cell lines predicts resistance towards 11 anticancer drugs at clinically achieved concentrations. Int J Cancer 118: 1699–1712CrossRefPubMed Györffy B, Surowiak P, Kiesslich O et al. (2006) Gene expression profiling of 30 cancer cell lines predicts resistance towards 11 anticancer drugs at clinically achieved concentrations. Int J Cancer 118: 1699–1712CrossRefPubMed
37.
Zurück zum Zitat Hofmann WK, de Vos S, Elashoff D et al. (2002) Relation between resistance of Philadelphia-chromosome-positive acute lymphoblastic leukaemia to the tyrosine kinase inhibitor STI571 and geneexpression profiles: a gene-expression study. Lancet 359: 481–486CrossRefPubMed Hofmann WK, de Vos S, Elashoff D et al. (2002) Relation between resistance of Philadelphia-chromosome-positive acute lymphoblastic leukaemia to the tyrosine kinase inhibitor STI571 and geneexpression profiles: a gene-expression study. Lancet 359: 481–486CrossRefPubMed
38.
Zurück zum Zitat Ioannidis JPA (2005) Microarrays and molecular research: noise discovery? Lancet 365: 454–455PubMed Ioannidis JPA (2005) Microarrays and molecular research: noise discovery? Lancet 365: 454–455PubMed
39.
Zurück zum Zitat Jacquemier J, Ginestier C, Rougemont J et al. (2005) Protein expression profiling identifies subclasses of breast cancer and predicts prognosis. Cancer Res 65: 767–779PubMed Jacquemier J, Ginestier C, Rougemont J et al. (2005) Protein expression profiling identifies subclasses of breast cancer and predicts prognosis. Cancer Res 65: 767–779PubMed
40.
Zurück zum Zitat Jones PA, Baylin SB (2002) The fundamental role of epigenetic events in cancer. Nat Rev Genet 3: 415–428CrossRefPubMed Jones PA, Baylin SB (2002) The fundamental role of epigenetic events in cancer. Nat Rev Genet 3: 415–428CrossRefPubMed
41.
Zurück zum Zitat Khan J, Wei JS, Ringner M et al. (2001) Classification and diagnostic prediction of cancers using gene expression profiling and artificial neural networks. Nat Med 7: 673–679CrossRefPubMed Khan J, Wei JS, Ringner M et al. (2001) Classification and diagnostic prediction of cancers using gene expression profiling and artificial neural networks. Nat Med 7: 673–679CrossRefPubMed
42.
Zurück zum Zitat Khan J, Simon R, Bittner M et al. (1998) Gene expression profiling of alveolar rhabdomyosarcoma with cDNA microarrays. Cancer Res 58: 5009–5013PubMed Khan J, Simon R, Bittner M et al. (1998) Gene expression profiling of alveolar rhabdomyosarcoma with cDNA microarrays. Cancer Res 58: 5009–5013PubMed
43.
Zurück zum Zitat Kihara C, Tsunoda T, Tanaka T et al. (2001) Prediction of sensitivity of esophageal tumors to adjuvant chemotherapy by cDNA microarray analysis of gene-expression profiles. Cancer Res 61: 6474–6479PubMed Kihara C, Tsunoda T, Tanaka T et al. (2001) Prediction of sensitivity of esophageal tumors to adjuvant chemotherapy by cDNA microarray analysis of gene-expression profiles. Cancer Res 61: 6474–6479PubMed
44.
Zurück zum Zitat Kreunin P, Urquidi V, Lubman DM et al. (2004) Identification of metastasis-associated proteins in a human tumor metastasis model using the mass-mapping technique. Proteomics 4: 2754–2765CrossRefPubMed Kreunin P, Urquidi V, Lubman DM et al. (2004) Identification of metastasis-associated proteins in a human tumor metastasis model using the mass-mapping technique. Proteomics 4: 2754–2765CrossRefPubMed
45.
Zurück zum Zitat Lage H, Dietel M (2000) Effect of the breast-cancer resistance protein on atypical multidrug resistance. Lancet Oncol 1: 169–175CrossRefPubMed Lage H, Dietel M (2000) Effect of the breast-cancer resistance protein on atypical multidrug resistance. Lancet Oncol 1: 169–175CrossRefPubMed
46.
Zurück zum Zitat Lage H, Perlitz C, Abele R et al. (2001) Enhanced expression of human ABC-transporter tap is associated with cellular resistance to mitoxantrone. FEBS Lett 503: 179–184CrossRefPubMed Lage H, Perlitz C, Abele R et al. (2001) Enhanced expression of human ABC-transporter tap is associated with cellular resistance to mitoxantrone. FEBS Lett 503: 179–184CrossRefPubMed
47.
Zurück zum Zitat Lakhani SR (2001) Molecular genetics of solid tumours: translating research into clinical practice. What we could do now: breast cancer. J Clin Pathol Mol Pathol 54: 281–284 Lakhani SR (2001) Molecular genetics of solid tumours: translating research into clinical practice. What we could do now: breast cancer. J Clin Pathol Mol Pathol 54: 281–284
48.
Zurück zum Zitat Liu Y, Liu H, Han B et al. (2006) Identification of 14–3-3sigma as a contributor to drug resistance in human breast cancer cells using functional proteomic analysis. Cancer Res 66: 3248–3255CrossRefPubMed Liu Y, Liu H, Han B et al. (2006) Identification of 14–3-3sigma as a contributor to drug resistance in human breast cancer cells using functional proteomic analysis. Cancer Res 66: 3248–3255CrossRefPubMed
49.
Zurück zum Zitat Ma XJ, Salunga R, Tuggle JT et al. (2003) Gene expression profiles of human breast cancer progression. Proc Natl Acad Sci USA 100: 5974–5979CrossRefPubMed Ma XJ, Salunga R, Tuggle JT et al. (2003) Gene expression profiles of human breast cancer progression. Proc Natl Acad Sci USA 100: 5974–5979CrossRefPubMed
50.
Zurück zum Zitat Mian S, Ugurel S, Parkinson E et al. (2005) Serum proteomic fingerprinting discriminates between clinical stages and predicts disease progression in melanoma patients. J Clin Oncol 23: 5088–5093CrossRefPubMed Mian S, Ugurel S, Parkinson E et al. (2005) Serum proteomic fingerprinting discriminates between clinical stages and predicts disease progression in melanoma patients. J Clin Oncol 23: 5088–5093CrossRefPubMed
51.
Zurück zum Zitat Michiels MS, Koscielny S, Hill C (2005) Prediction of cancer outcome with microarrays: a multiple random validation strategy. Lancet 365: 488–492CrossRefPubMed Michiels MS, Koscielny S, Hill C (2005) Prediction of cancer outcome with microarrays: a multiple random validation strategy. Lancet 365: 488–492CrossRefPubMed
52.
Zurück zum Zitat Neubauer H, Clare SE, Kurek R et al. (2006) Breast cancer proteomics by laser capture microdissection, sample pooling, 54-cm IPG IEF, and differential iodine radioisotope detection. Electrophoresis 27: 1840–1852CrossRefPubMed Neubauer H, Clare SE, Kurek R et al. (2006) Breast cancer proteomics by laser capture microdissection, sample pooling, 54-cm IPG IEF, and differential iodine radioisotope detection. Electrophoresis 27: 1840–1852CrossRefPubMed
53.
Zurück zum Zitat Ono K, Tanaka T, Tsunoda T et al. (2000) Identification by cDNA microarray of genes involved in ovarian carcinogenesis. Cancer Res 60: 5007–5011PubMed Ono K, Tanaka T, Tsunoda T et al. (2000) Identification by cDNA microarray of genes involved in ovarian carcinogenesis. Cancer Res 60: 5007–5011PubMed
54.
Zurück zum Zitat Perou CM, Sorlie T, Eisen MB et al. (2000) Molecular portraits of human breast tumours. Nature 406: 747–752CrossRefPubMed Perou CM, Sorlie T, Eisen MB et al. (2000) Molecular portraits of human breast tumours. Nature 406: 747–752CrossRefPubMed
55.
Zurück zum Zitat Reis-Filho JS, Westbury C, Pierga JY (2006) The impact of expression profiling on prognostic and predictive testing in brest cancer. J Clin Path 59: 225–231CrossRefPubMed Reis-Filho JS, Westbury C, Pierga JY (2006) The impact of expression profiling on prognostic and predictive testing in brest cancer. J Clin Path 59: 225–231CrossRefPubMed
56.
Zurück zum Zitat Ricolleau G, Charbonnel C, Lode L et al. (2006) Surface-enhanced laser desorption/ionization time of flight mass spectrometry protein profiling identifies ubiquitin and ferritin light chain as prognostic biomarkers in node-negative breast cancer tumors. Proteomics 6: 1963–1975CrossRefPubMed Ricolleau G, Charbonnel C, Lode L et al. (2006) Surface-enhanced laser desorption/ionization time of flight mass spectrometry protein profiling identifies ubiquitin and ferritin light chain as prognostic biomarkers in node-negative breast cancer tumors. Proteomics 6: 1963–1975CrossRefPubMed
57.
Zurück zum Zitat Scherf U, Ross DT, Waltham M et al. (2000) A gene expression database for the molecular pharmacology of cancer. Nat Genet 24: 236–244CrossRefPubMed Scherf U, Ross DT, Waltham M et al. (2000) A gene expression database for the molecular pharmacology of cancer. Nat Genet 24: 236–244CrossRefPubMed
58.
Zurück zum Zitat Schwartz SA, Weil RJ, Thompson RC et al. (2005) Proteomic-based prognosis of brain tumor patients using direct-tissue matrix-assisted laser desorption ionization mass spectrometry. Cancer Res 65: 7674–7681PubMed Schwartz SA, Weil RJ, Thompson RC et al. (2005) Proteomic-based prognosis of brain tumor patients using direct-tissue matrix-assisted laser desorption ionization mass spectrometry. Cancer Res 65: 7674–7681PubMed
59.
Zurück zum Zitat Schwartz DR, Kardia SL, Shedden KA et al. (2002) Gene expression in ovarian cancer reflects both morphology and biological behavior, distinguishing clear cell from other poor-prognosis ovarian carcinomas. Cancer Res 62: 4722–4729PubMed Schwartz DR, Kardia SL, Shedden KA et al. (2002) Gene expression in ovarian cancer reflects both morphology and biological behavior, distinguishing clear cell from other poor-prognosis ovarian carcinomas. Cancer Res 62: 4722–4729PubMed
60.
Zurück zum Zitat Sinha P, Poland J, Kohl S et al. (2003) Study of the development of chemoresistance in melanoma cell lines using proteome analysis. Electrophoresis 24: 2386–2404CrossRefPubMed Sinha P, Poland J, Kohl S et al. (2003) Study of the development of chemoresistance in melanoma cell lines using proteome analysis. Electrophoresis 24: 2386–2404CrossRefPubMed
61.
Zurück zum Zitat Sinha P, Poland J, Schnolzer M et al. (2001) Characterization of the differential protein expression associated with thermoresistance in human gastric carcinoma cell lines. Electrophoresis 22: 2990–3000CrossRefPubMed Sinha P, Poland J, Schnolzer M et al. (2001) Characterization of the differential protein expression associated with thermoresistance in human gastric carcinoma cell lines. Electrophoresis 22: 2990–3000CrossRefPubMed
62.
Zurück zum Zitat Sobin L, Wittekind C (2002) TNM classification of malignant tumors (6th ed); UICC. Wiley, New Jersey Sobin L, Wittekind C (2002) TNM classification of malignant tumors (6th ed); UICC. Wiley, New Jersey
63.
Zurück zum Zitat Sorlie T, Perou CM, Tibshirani R et al. (2001) Gene expression patterns of breast carcinomas distinguish tumor subclasses with clinical implications. Proc Natl Acad Sci USA 98: 10869–10874CrossRefPubMed Sorlie T, Perou CM, Tibshirani R et al. (2001) Gene expression patterns of breast carcinomas distinguish tumor subclasses with clinical implications. Proc Natl Acad Sci USA 98: 10869–10874CrossRefPubMed
64.
Zurück zum Zitat Sotiriou C, Neo SY, McShane LM et al. (2003) Breast cancer classification and prognosis based on gene expression profiles from a population-based study. Proc Natl Acad Sci USA 100: 10393–10398CrossRefPubMed Sotiriou C, Neo SY, McShane LM et al. (2003) Breast cancer classification and prognosis based on gene expression profiles from a population-based study. Proc Natl Acad Sci USA 100: 10393–10398CrossRefPubMed
65.
Zurück zum Zitat Stanta G, Mucelli SP, Petrera F et al. (2006) A novel fixative improves opportunities of nucleic acids and proteomic analysis in human archive’s tissues. Diagn Mol Pathol 15: 115–123CrossRefPubMed Stanta G, Mucelli SP, Petrera F et al. (2006) A novel fixative improves opportunities of nucleic acids and proteomic analysis in human archive’s tissues. Diagn Mol Pathol 15: 115–123CrossRefPubMed
66.
Zurück zum Zitat Stoeckli M, Chaurand P, Hallahan DE et al. (2001) Imaging mass spectrometry: a new technology for the analysis of protein expression in mammalian tissues. Nat Med 7: 493–496CrossRefPubMed Stoeckli M, Chaurand P, Hallahan DE et al. (2001) Imaging mass spectrometry: a new technology for the analysis of protein expression in mammalian tissues. Nat Med 7: 493–496CrossRefPubMed
67.
Zurück zum Zitat Su AI, Welsh JB, Sapinoso LM et al. (2001) Molecular classification of human carcinomas by use of gene expression signatures. Cancer Res 61: 7388–7393PubMed Su AI, Welsh JB, Sapinoso LM et al. (2001) Molecular classification of human carcinomas by use of gene expression signatures. Cancer Res 61: 7388–7393PubMed
68.
Zurück zum Zitat Tan PK, Downey TJ, Spitznagel EL Jr et al. (2003) Evaluation of gene expression measurements from commercial microarray platforms. Nucleic Acids Res 31: 5676–5684CrossRefPubMed Tan PK, Downey TJ, Spitznagel EL Jr et al. (2003) Evaluation of gene expression measurements from commercial microarray platforms. Nucleic Acids Res 31: 5676–5684CrossRefPubMed
69.
Zurück zum Zitat Thuerigen O, Schneeweiss A, Toedt G et al. (2006) Gene expression signature predicting pathologic complete response with gemcitabine, epirubicin, and docetaxel in primary breast cancer. J Clin Oncol 24: 1839–1845CrossRefPubMed Thuerigen O, Schneeweiss A, Toedt G et al. (2006) Gene expression signature predicting pathologic complete response with gemcitabine, epirubicin, and docetaxel in primary breast cancer. J Clin Oncol 24: 1839–1845CrossRefPubMed
70.
Zurück zum Zitat Veer LJ van’t, Dai H, Vijver MJ van de et al. (2002) Gene expression profiling predicts clinical outcome of breast cancer. Nature 415: 484–485CrossRefPubMed Veer LJ van’t, Dai H, Vijver MJ van de et al. (2002) Gene expression profiling predicts clinical outcome of breast cancer. Nature 415: 484–485CrossRefPubMed
71.
Zurück zum Zitat Vihinen PP, Pyrhonen SO, Kahari VM (2003) New prognostic factors and developing therapy of cutaneous melanoma. Ann Med 35: 66–78CrossRefPubMed Vihinen PP, Pyrhonen SO, Kahari VM (2003) New prognostic factors and developing therapy of cutaneous melanoma. Ann Med 35: 66–78CrossRefPubMed
72.
Zurück zum Zitat Wang SS, Sherman ME, Rader JS et al. (2006) Cervical tissue collection methods for RNA preservation: comparison of snap-frozen, ethanol-fixed, and RNAlater-fixation. Diagn Mol Pathol 15: 144–148CrossRefPubMed Wang SS, Sherman ME, Rader JS et al. (2006) Cervical tissue collection methods for RNA preservation: comparison of snap-frozen, ethanol-fixed, and RNAlater-fixation. Diagn Mol Pathol 15: 144–148CrossRefPubMed
73.
Zurück zum Zitat Wang W, Marsh S, Cassidy J et al. (2001) Pharmacogenomic dissection of resistance to thymidylate synthase inhibitors. Cancer Res 61: 5505–5510PubMed Wang W, Marsh S, Cassidy J et al. (2001) Pharmacogenomic dissection of resistance to thymidylate synthase inhibitors. Cancer Res 61: 5505–5510PubMed
74.
Zurück zum Zitat Wang Y, Klijn JG, Zhang Y et al. (2005) Geneexpression profiles to predict distant metastasis of lymph-nodenegative primary breast cancer. Lancet 365: 671–679PubMed Wang Y, Klijn JG, Zhang Y et al. (2005) Geneexpression profiles to predict distant metastasis of lymph-nodenegative primary breast cancer. Lancet 365: 671–679PubMed
75.
Zurück zum Zitat Willipinski-Stapelfeldt B, Riethdorf S, Assmann V et al. (2005) Changes in cytoskeletal protein composition indicative of an epithelial-mesenchymal transition in human micrometastatic and primary breast carcinoma cells. Clin Cancer Res 11: 8006–8014CrossRefPubMed Willipinski-Stapelfeldt B, Riethdorf S, Assmann V et al. (2005) Changes in cytoskeletal protein composition indicative of an epithelial-mesenchymal transition in human micrometastatic and primary breast carcinoma cells. Clin Cancer Res 11: 8006–8014CrossRefPubMed
76.
Zurück zum Zitat Yeoh EJ, Ross ME, Shurtleff SA et al. (2002) Classification, subtype discovery, and prediction of outcome in pediatric acute lymphoblastic leukemia by gene expression profiling. Cancer Cell 1: 133–143CrossRefPubMed Yeoh EJ, Ross ME, Shurtleff SA et al. (2002) Classification, subtype discovery, and prediction of outcome in pediatric acute lymphoblastic leukemia by gene expression profiling. Cancer Cell 1: 133–143CrossRefPubMed
77.
Zurück zum Zitat Zembutsu H, Ohnishi Y, Tsunoda T et al. (2002) Genome-wide cDNA microarray screening to correlate gene expression profiles with sensitivity of 85 human cancer xenografts to anticancer drugs. Cancer Res 62: 518–527PubMed Zembutsu H, Ohnishi Y, Tsunoda T et al. (2002) Genome-wide cDNA microarray screening to correlate gene expression profiles with sensitivity of 85 human cancer xenografts to anticancer drugs. Cancer Res 62: 518–527PubMed
Metadaten
Titel
Prädiktive Biomarker
Die Schlüsselrolle der Molekularpathologie
verfasst von
Prof. Dr. M. Dietel
Publikationsdatum
01.01.2007
Verlag
Springer-Verlag
Erschienen in
Die Onkologie / Ausgabe 1/2007
Print ISSN: 2731-7226
Elektronische ISSN: 2731-7234
DOI
https://doi.org/10.1007/s00761-006-1154-z

Weitere Artikel der Ausgabe 1/2007

Der Onkologe 1/2007 Zur Ausgabe

Neu im Fachgebiet Onkologie

Die beste Jahreszeit für eine Krebsimmuntherapie

16.07.2024 Onkologische Immuntherapie Nachrichten

Die Wirksamkeit von Checkpointhemmern scheint klinisch relevanten saisonalen Schwankungen zu unterliegen. Patienten mit fortgeschrittenem nichtkleinzelligem Lungenkarzinom etwa hatten das beste Outcome, wenn die PD-1-Inhibitor-Infusionen in den Wintermonaten starteten.

Partielle Nephrektomie: Videoanalysen zur Verbesserung der chirurgischen Qualität

16.07.2024 Nephrektomie Nachrichten

Je versierter Operateurinnen und Operateure sind, desto geringer ist das Risiko für Komplikationen. Eine kleine US-Studie spricht dafür, dass das auch bei Roboter-assistierten Nephrektomien gilt – und dass sich Op.-Videos für die Beurteilung eignen.        

S3-Leitlinie Endometriumkarzinom aktualisiert

15.07.2024 Endometriumkarzinom Nachrichten

Die angepasste Version der S3-Leitlinie Endometriumkarzinom enthält unter anderem Empfehlungen zu Risikofaktoren, wie der Hormonersatztherapie, sowie darüber, wann eine vaginale Brachytherapie und wann eine Perkutanbestrahlung angebracht ist.

Warum junge Brustkrebspatientinnen die endokrine Therapie absetzen

15.07.2024 Mammakarzinom Nachrichten

Bei jungen Brustkrebspatientinnen ist die Wahrscheinlichkeit groß, dass sie eine adjuvante endokrine Therapie vorzeitig absetzen. In einer europäischen Kohorte wurden dafür zwei Risikofaktoren identifiziert, die bei der Behandlung berücksichtigt werden sollten.

Update Onkologie

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.